Document is current

Article History

Received: 19 September 2024

Accepted: 19 December 2024

First Online: 22 January 2025

Declarations

:

: L.C.V. declares consulting with Astrazeneca, EMD Serono, Sanofi, Daiichi Sankyo, Gilead, Jazz, Johnson and Johnson, Takeda, BMS, and Bayer. D.D. declares the following: Grants/Research Support (institutional): Arcus, Immunocore, Merck, Regeneron Pharmaceuticals Inc., Tesaro/GSK; Consultant: ACM Bio, Ascendis, Castle, Clinical Care Options (CCO), Gerson Lehrman Group (GLG), Immunitas, Medical Learning Group (MLG), Replimmune, Trisalus, Xilio Therapeutics; CE Speakers’ Bureau: Castle Biosciences. Steering Committee/DSMC: Replimmune, Immunocore; Stockholder: Zola. R.H.M. declares consulting/advisory board with Nimbus Therapeutics, IDEAYA Biosciences, Puretech Health; research funding (institutional) from Repare Therapeutics, Nimbus Therapeutics.

: This was an NCI, CTEP sponsored, multicenter trial performed at four NCI-designated cancer centers, approved by the respective institutional review boards and ethics committees, under the NCI CIRB as the IRB of record. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was registered under ClinicalTrials.gov Identifier: NCT04535401.

: Not applicable.